Treat to target in gout

Not Applicable

• Conditions: Gout; Musculoskeletal Diseases

• Registration Number: ISRCTN12059648
• Lead Sponsor: niversity of Nottingham

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-06-12
• Last Update Posted: 21 May 2024
• Study Completion: 2028-05-02

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 468

Inclusion Criteria

1. Age =18 years
2. Ability to give informed consent
3. Meets the clinical American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria for gout
4. =1 flare of gout in the previous 12 months
5. Serum urate =360 µmol/L regardless of current ULT

Exclusion Criteria

1. Previous allopurinol side-effects that contraindicate its prescription
2. Dementia, severe enduring mental illness i.e. mental health illness that makes receiving the study information and initial screening questionnaire from GP a stressful experience
3. Unable to comply with study procedures
4. Life expectancy less than 12 months
5. Cancer treatment, i.e. surgery, radiotherapy, or chemotherapy in the previous 12 months
6. Solid organ transplant
7. Cirrhosis
8. Autoimmune rheumatic disease i.e. rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, connective tissue diseases, vasculitis, giant cell arteritis, polymyalgia rheumatica, inflammatory arthritis associated with inflammatory bowel disease, reactive arthritis, ankylosing spondylitis
9. Inflammatory bowel disease
10. Current long-term daily oral corticosteroid treatment defined as continuous use for =30 days or current immunosuppressive treatments
11. Stage 4/5 CKD i.e. eGFR < 30 ml/min
12. Pregnant, breastfeeding or planning to become pregnant in the next 4 years

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of gout flares in the first 2 years measured by patient initiated SMS service or acute gout flare diary